World Investment Advisors Buys 1,061 Shares of IDEXX Laboratories, Inc. $IDXX

World Investment Advisors lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 126.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,902 shares of the company’s stock after purchasing an additional 1,061 shares during the quarter. World Investment Advisors’ holdings in IDEXX Laboratories were worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $31,000. Finally, Greykasell Wealth Strategies Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $35,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IDXX. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, UBS Group reduced their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

Insider Activity

In other news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This represents a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 34,612 shares of company stock valued at $22,525,070. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $528.79 on Monday. IDEXX Laboratories, Inc. has a fifty-two week low of $496.61 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market capitalization of $41.71 billion, a price-to-earnings ratio of 38.94, a PEG ratio of 3.07 and a beta of 1.58. The company’s 50 day moving average price is $572.08 and its two-hundred day moving average price is $645.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the firm posted $2.91 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.